Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $89.90 Consensus Target Price from Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has earned an average rating of “Buy” from the thirteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $89.90.

A number of research firms have commented on JANX. Scotiabank raised their price objective on Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 4th. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. Stifel Nicolaus upped their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $200.00 target price on shares of Janux Therapeutics in a research report on Wednesday, December 11th.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 13,334 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the transaction, the insider now owns 82,139 shares in the company, valued at $4,507,788.32. This represents a 13.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David Alan Campbell sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the sale, the chief executive officer now directly owns 293,054 shares of the company’s stock, valued at approximately $17,583,240. This represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 108,334 shares of company stock worth $6,070,020. Insiders own 29.40% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors have recently added to or reduced their stakes in JANX. Plato Investment Management Ltd boosted its stake in Janux Therapeutics by 18.7% in the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after acquiring an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the last quarter. Amalgamated Bank grew its holdings in Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after purchasing an additional 368 shares during the period. Virtu Financial LLC increased its position in Janux Therapeutics by 48.0% in the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock worth $339,000 after buying an additional 2,419 shares during the last quarter. Finally, Avanza Fonder AB bought a new stake in shares of Janux Therapeutics in the fourth quarter valued at $139,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Up 0.3 %

NASDAQ JANX opened at $40.72 on Wednesday. The firm’s 50 day moving average is $53.09 and its 200-day moving average is $48.41. Janux Therapeutics has a 12-month low of $7.79 and a 12-month high of $71.71. The company has a market capitalization of $2.14 billion, a PE ratio of -34.80 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. The company’s quarterly revenue was down 82.6% on a year-over-year basis. As a group, sell-side analysts expect that Janux Therapeutics will post -1.38 EPS for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.